ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 53 of 53 for:    HISTIDINE OR HISTIDINE MONOHYDROCHLORIDE

Identification of Donors of CD36-Deficient Platelets Among Japanese Individuals on the NIH Campus

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00015639
Recruitment Status : Completed
First Posted : April 26, 2001
Last Update Posted : March 4, 2008
Sponsor:
Information provided by:
National Institutes of Health Clinical Center (CC)

Brief Summary:
Plasma histidine-rich glycoprotein (HRG) binds to platelets in the presence of zinc (1). This binding is totally blocked by a monoclonal antibody directed against platelet membrane CD36. Therefore, CD36 is assumed to carry the platelet binding site for HRG (2). Because CD36 also has a variety of other ligands, including polyanionic lipids, it is also possible that it contains the binding site for heparin (also polyanionic) and might be involve in the pathogenesis of heparin-induced thrombocytopenia. Demonstrating absent HRG or heparin binding to platelets lacking CD36 would confirm that the binding sites for either or both of these ligands are located on this membrane protein. Because 3% to 11% of healthy Japanese are reported to lack CD36 on their platelets, this population is a practical source of cells for examining the physiologic role(s) for CD36. Therefore, we will recruit blood donors from the Japanese community on the NIH campus. Their platelets will tested for the presence of CD36. Recruitment will be closed after two individuals have been identified whose platelets lack CD36 and who are willing to donate 30 cc of blood on 4 or 5 subsequent occasions for binding studies with radiolabeled HRG and heparin.

Condition or disease
Thrombocytopenia

Detailed Description:
Plasma histidine-rich glycoprotein (HRG) binds to platelets in the presence of zinc (1). This binding is totally blocked by a monoclonal antibody directed against platelet membrane CD36. Therefore, CD36 is assumed to carry the platelet binding site for HRG (2). Because CD36 also has a variety of other ligands, including polyanionic lipids, it is also possible that it contains the binding site for heparin (also polyanionic) and might be involved in the pathogenesis of heparin-induced thrombocytopenia. Demonstrating absent HRG or heparin binding to platelets lacking CD36 would confirm that the binding sites for either or both of these ligands are located on this membrane protein. Because 3% to 11% of healthy Japanese are reported to lack CD36 on their platelets, this population is a practical source of cells for examining the physiologic role(s) for CD36. It has also been reported that 2.4% of African Americans and 4% of Taiwanese lack this protein on their platelets. Therefore, we will recruit blood donors from the Japanese, African American, and Taiwanese community on the NIH campus. Their platelets will be tested for the presence of CD36. Recruitment will be closed after two individuals have been identified whose platelets lack CD36 and who are willing to donate 30 cc of blood on 4 or 5 subsequent occasions for binding studies with radiolabeled HRG and heparin.

Study Type : Observational
Enrollment : 150 participants
Official Title: Identification of Donors of CD36-Deficient Platelets Among Individuals on the NIH Campus
Study Start Date : April 2001
Study Completion Date : February 2004




Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

INCLUSION CRITERIA:

Phase I:

Full Japanese, African American, and Taiwanese ancestry

At least 18 years of age.

Willingness and ability to participate in Phase II of the study.

Must be able to provide written informed consent.

Phase II:

Less than 1% CD36 present on platelets, compared with controls.

EXCLUSION CRITERIA:

Phase I:

A history of anemia or thrombocytopenia.

Unwillingness or inability to participate in Phase II of the study.

Phase II:

Discovery of anemia (hemoglobin less than 11.1 g/dL for women, less than 12.7 for men) or thrombocytopenia (less than 162,000/microliter for women, less than 154,000/microliter for men) in the blood counts performed during Phase I.

Subjects will not be excluded because of any medications.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00015639


Locations
United States, Maryland
Warren G. Magnuson Clinical Center (CC)
Bethesda, Maryland, United States, 20892
Sponsors and Collaborators
National Institutes of Health Clinical Center (CC)

Publications:
ClinicalTrials.gov Identifier: NCT00015639     History of Changes
Other Study ID Numbers: 010156
01-CC-0156
First Posted: April 26, 2001    Key Record Dates
Last Update Posted: March 4, 2008
Last Verified: February 2004

Keywords provided by National Institutes of Health Clinical Center (CC):
Blood Donors
Employees
Heparin
Histidine-Rich Glycoprotein
Membrane
Healthy Volunteer

Additional relevant MeSH terms:
Thrombocytopenia
Blood Platelet Disorders
Hematologic Diseases